We also used CAL-101, a drug targeting the p110δ subunit of PI3K, which demonstrated clinical efficacy against chronic lymphocytic leukemia and colon cancer cells regardless of p53 mutational status [53]. This evidence concerns the gene TP53 and malignant colon neoplasm.